|
|
Article: After Phase IIa Failure.(stocks and management of Cypress Bioscience Inc.)
- Article from:
- BIOWORLD Today
- Article date:
- June 28, 2006
- Author:
CopyrightCOPYRIGHT 2006 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Cypress, Organon Mull Future Of Mirtazapine Collaboration, , By Randall Osborne, West Coast Editor
Cypress Bioscience Inc. said results from Phase IIa trials do not support going ahead with mirtazapine combined with another approved drug for obstructive sleep apnea, although an earlier pilot trial yielded encouraging results.
With partner Organon Ltd., of Dublin, Ireland, Cypress is "exploring new potential opportunities to continue the collaboration," according to a press release. The company could not be reached for comment.
Cypress' stock (NASDAQ:CYPB) closed Tuesday at $5.84, down 22 cents, after trading as low as $5.26.
...